Andreatta K. et al.: Prevalence and Risk Factors of Preexisting TAMs in Clinical Trial Participants and Sustained Viral Suppression After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Zurück zur Übersicht

27.-30.10.2021 / EACS